Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 11/20 | 0.44 |
| ▸ | HTR1B | P28222 | 11/20 | 0.44 |
| ▸ | HTR1A | P08908 | 9/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4633738 | 0.91 | HTR1D (0.53) | HTR1DHTR1BHTR1AHTTLMNA | |
| SCHEMBL4832197 | 0.89 | HTR1D (0.51) | HTR1DHTR1BHTR1AHTTLMNA | |
| SCHEMBL4829986 | 0.89 | ADRA2A (0.52) | HTR1DHTR1BHTR1AHTTLMNA | |
| SCHEMBL14279517 | 0.88 | HTR1D (0.48) | HTR1DHTR1BHTR1AHTTLMNA | |
| SCHEMBL4832616 | 0.88 | HTR1D (0.46) | HTR1DHTR1BHTR1AHTTLMNA | |
| SCHEMBL4828140 | 0.88 | HTT (0.53) | HTR1DHTR1BHTR1AHTTLMNA | |
| SCHEMBL4832775 | 0.88 | HTR1D (0.49) | HTR1DHTR1BHTR1AHTTLMNA | |
| SCHEMBL14279522 | 0.87 | ADRA2A (0.42) | HTR1DHTR1BHTR1AHTTLMNA | |
| SCHEMBL14279496 | 0.86 | HTR1D (0.46) | HTR1DHTR1BHTR1AHTTLMNA | |
| SCHEMBL4834061 | 0.86 | HTR1D (0.60) | HTR1DHTR1BHTR1AHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | HTR1D 533/4885HTR1B 342/4885HTR1A 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.